false
0001704287
0001704287
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2026

BLUEJAY DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
| delaware |
|
001-41031 |
|
47-3552922 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission File No.) |
|
(I.R.S. Employer
Identification No.) |
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
(Address of principal executive offices
and zip code)
(844) 327-7078
(Registrant’s telephone number, including
area code)
(Former
name or former address, if changed from last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
| |
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol (s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
BJDX |
|
The Nasdaq Stock Market LLC |
| Item 2.02 |
Results of Operations and Financial Condition. |
On November 12, 2026, Bluejay Diagnostics, Inc.
issued a press release providing a corporate update, as well as certain financial results as of and for the fiscal quarter ended September
30, 2026. A copy of that press release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current
Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities
Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange
Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated
by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 |
|
Press release, dated November 12, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
| |
Bluejay Diagnostics, Inc. |
| |
|
|
|
By: |
/s/ Neil Dey |
| |
|
Neil Dey |
| |
|
President and Chief Executive Officer |
Date: November 13,
2026
Exhibit 99.1

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results
and Provides Business Update
Completes SYMON-II clinical study enrollment and advances clinical
validation activities
Achieves critical manufacturing milestone ahead of contractual deadline,
strengthening supply chain and commercialization readiness
Targets FDA 510(k) submission in the first half of 2027
ACTON, Mass., November 12, 2026 — Bluejay Diagnostics,
Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid, near-patient
testing solutions for critical care, today reported financial results for the quarter ended September 30, 2026, and provided an update
on its clinical, regulatory and manufacturing progress for the Symphony™ platform.
During the quarter and subsequent weeks, Bluejay achieved several important
milestones, including completion of enrollment in its SYMON-II clinical validation study, establishment of an alternative manufacturing
facility ahead of a contractual deadline, and continued advancement of its U.S. manufacturing and commercialization infrastructure.
“The third quarter marked significant progress for Bluejay as
we advanced several critical elements toward regulatory submission and commercialization,” said Neil Dey, President and Chief Executive
Officer. “With SYMON-II enrollment completed, important manufacturing milestones achieved, and U.S. supply chain infrastructure
enhanced, I believe that we have meaningfully reduced several key development and operational risks. Going forward, our focus remains
on completing clinical and analytical validation and preparing for company’s planned FDA submission in the first half of 2027.”
Third Quarter and Recent Business Highlights
Clinical Development and Regulatory Progress
| ● | Successfully completed SYMON-II clinical study enrollment, exceeding the original target of 750 patients. |
| ● | Preliminary baseline analysis of 777 evaluable patients identified 140 deaths within 28 days, representing approximately 18% mortality,
providing a substantial clinical dataset for evaluating IL-6 prognostic performance. |
| ● | Initiated preliminary sample testing and patient data analysis, with final analytical testing to follow cartridge verification and
validation. |
| ● | Continued advancing toward a planned FDA 510(k) submission for Symphony IL-6 during the first half of 2027, subject to successful
validation. |
Manufacturing and Commercial Readiness
| ● | Established an alternative Symphony cartridge manufacturing site through Sanyoseiko ahead of the October 23, 2026 contractual deadline
under the Company’s agreement with Toray Industries. |
| ● | Advanced U.S. manufacturing capabilities through ALURIS Sciences (previously Argonaut Manufacturing), supporting cartridge production,
quality activities, packaging and distribution. |
| ● | Continued developing commercial infrastructure, including a entering into a distribution agreement with Lovell Government Services
to support potential access to U.S. government healthcare markets. |
| ● | Progressed an exploratory artificial intelligence initiative evaluating the potential integration of IL-6 measurements and clinical
data for future sepsis risk stratification applications. |
These initiatives are intended to strengthen manufacturing reliability,
reduce supply chain concentration risk and support potential commercialization following regulatory authorization.
As of September 30, 2026, Bluejay had $7.38 million in cash and cash
equivalents, compared with $5.16 million at December 31, 2025.
Net cash used in operating activities for the nine months ended September
30, 2026 was approximately $5.09 million. Based on current operating plans, the Company estimates that existing cash resources will support
operations through the second quarter of 2027. Additional financing will be required to support its longer-term development and commercialization
plans.
Outlook
Bluejay remains focused on completing SYMON-II clinical analysis, advancing
analytical validation and manufacturing qualification, and preparing its planned FDA 510(k) submission during the first half of 2027.
“Our achievements in clinical development and manufacturing have
positioned us to focus on the next critical phase of execution towards commercial readiness,” continued Mr. Dey. “We remain
committed to disciplined capital allocation, regulatory progress and building a scalable diagnostic platform with the potential to address
important unmet needs in critical care.”
Potential Importance of Rapid IL-6 Information
Sepsis is a highly heterogeneous and rapidly evolving condition. Patients
presenting with severe infection may follow substantially different clinical trajectories, creating a need for timely information that
can help clinicians assess patient risk.
Bluejay is developing the Symphony™ Suite as a rapid quantitative
biomarker assay platform. The Company’s development strategy is intended to bring quantitative biomarker information closer to the
patient and make results available rapidly enough to potentially complement clinical assessment and established measures of disease severity.
The Company is continuing its analysis of clinical samples and data
as part of its SYMON-II pivotal study, including evaluation of IL-6 measurements and their relationship to 28-day mortality and other
relevant clinical parameters. The baseline characteristics announced to date do not themselves establish the prognostic performance, clinical
utility, sensitivity, specificity or regulatory acceptability of the Symphony™ IL-6 Test. Those conclusions will depend upon completion
of the planned analyses.
The Symphony™ IL-6 Test has not been cleared or approved
by the U.S. Food and Drug Administration (“FDA”) and is not currently available for commercial clinical use in the United
States.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov
ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with
various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal
study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to FDA. The SYMON-III
study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency
department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics,
Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid,
near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for
the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™
can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed
to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make
earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the
Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking
statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,”
“will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections
about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed
in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors”
in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk
Factors” in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026, June 30, 2026 and September
30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties,
and actual results and performance in future periods may not occur or may be materially different from any future results or performance
suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes
no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as
required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect
any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com